SCHEMBL807587

SCHEMBL807587

CC(C)[C@@H]1CCCN(Cc2csc3ccccc23)C1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
CRHBP P24387 1/20 0.60
CRHR2 Q13324 1/20 0.60
PDE2A O00408 1/20 0.52
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
DRD2 P14416 6/20 0.45
DRD4 P21917 5/20 0.45
DRD3 P35462 5/20 0.45
HTR1A P08908 1/20 0.43
FAAH O00519 1/20 0.43
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
OPRL1 P41146 1/20 0.43
SLC6A4 P31645 1/20 0.43
UTS2R Q9UKP6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15081976 1.00 CHRNA7 (0.61) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A
SCHEMBL15081937 0.93 CHRNA7 (0.57) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A
SCHEMBL15084307 0.84 CHRNA7 (0.66) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A
SCHEMBL807400 0.84 CHRNA7 (0.66) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A
SCHEMBL807180 0.81 CHRNA7 (0.51) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A
SCHEMBL807391 0.80 CHRNA7 (0.60) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A
SCHEMBL15081975 0.79 TSHR (0.66) SMN1; SMN2PDE2AFAAHOPRM1OPRK1
SCHEMBL807183 0.79 TSHR (0.66) SMN1; SMN2PDE2AFAAHOPRM1OPRK1
SCHEMBL15081977 0.79 TSHR (0.46) SMN1; SMN2OPRM1OPRK1OPRL1
SCHEMBL10210828 0.78 CHRNA7 (0.97) CHRNA7SMN1; SMN2CRHBPCRHR2PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
WO-2012036997-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS SCHERING CORPORATION (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 CHRNA7 4556/4885SMN1; SMN2 4597/4885CRHBP 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.